Welcome to our dedicated page for LEXICON PHARMACEUTICALS SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
Lexicon Pharmaceuticals granted equity awards to senior vice president of discovery Suma Gopinathan. On February 12, 2026, she acquired 238,450 restricted stock units, each representing one share of common stock, and a stock option for 357,680 shares at an exercise price of $1.37 per share.
The RSUs vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, then 1/48th of the shares each month of continued service until fully vested by February 12, 2036.
Lexicon Pharmaceuticals, Inc. reported equity awards to senior vice president Lisa DeFrancesco. On February 12, 2026, she received 257,530 restricted stock units, each representing a right to one share of common stock, and 386,300 stock options with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock options vest 25% on the first anniversary of grant, with the remaining portion vesting monthly over the following three years, contingent on continued service.
Lexicon Pharmaceuticals executive Brian T. Crum, SVP, General Counsel and Secretary, reported equity awards on February 12, 2026. He was granted 299,710 restricted stock units, each representing the right to receive one share of common stock as they vest.
The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. Crum was also granted a stock option for 449,560 shares at an exercise price of $1.37 per share, vesting 25% after one year and the remainder in equal monthly installments over the next three years.
Lexicon Pharmaceuticals SVP and CFO Scott M. Coiante received new equity awards as part of his compensation. On February 12, 2026, he was granted 272,680 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in three equal installments on February 28 of each of the three years after the grant year.
On the same date, he also received 409,020 stock options with an exercise price of $1.37 per share, expiring on February 12, 2036. The option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, all held as direct ownership.
Lexicon Pharmaceuticals’ Chief Executive Officer and director Michael Exton reported equity awards dated February 12, 2026. He received 862,440 restricted stock units, each representing a right to one share of common stock. These restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year.
He was also granted a stock option for 1,293,670 shares of common stock at an exercise price of $1.37 per share. The option vests 25% on the first anniversary of the grant date and then 1/48th of the shares each month of continued service thereafter.
Avicenna Life Sci Master Fund LP and its general partner Avicenna Life Sci Master GP LLC reported their initial insider status in Lexicon Pharmaceuticals. As of February 2, 2026, the fund indirectly beneficially owned 1,538,462 shares of Lexicon common stock.
The filing identifies both Avicenna entities as a director and 10% owner group, with the common stock directly held by Avicenna Life Sci Master Fund LP. The reporting persons disclaim beneficial ownership of securities held by the other related reporting persons except to the extent of their pecuniary interest.
Lexicon Pharmaceuticals disclosed significant share purchases by investment entities tied to Invus and Artal as part of a financing that closed on February 2, 2026. Artal Participations S.a r.l. agreed to buy 22,400,000 common shares at $1.30 per share, assigning the right to purchase 3,846,154 of those shares to Invus Public Equities, L.P., which bought them directly from Lexicon at the same price. Avicenna Life Sci Master Fund LP purchased 1,538,462 common shares as part of an underwritten public offering.
Artal Participations S.a r.l. also agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock at $65.00 per share and obtained the right to buy up to an additional 94,854.88 preferred shares at the same price. Each preferred share will automatically convert into 50 common shares once shareholder approval is obtained and specified conditions are met; until then, the preferred shares are not convertible. The filing notes complex ownership chains among Artal, Invus and related entities, and each reporting person disclaims beneficial ownership of securities held by the others beyond its pecuniary interest.
Lexicon Pharmaceuticals’ major shareholders have updated their ownership and financing arrangements following a new capital raise. An investor group led by Artal and Invus now collectively reports beneficial ownership of 205,952,227 Lexicon common shares, representing approximately 48.2% of the 427,084,567 shares outstanding as of the recent financing.
Artal Participations agreed to buy 22,400,000 common shares for $29,120,000 and 367,145.12 shares of Series B convertible preferred stock for $23,864,432.80 in private placements. Invus Public Equities purchased 3,846,154 common shares for $5,000,000.20, and Avicenna Life Sci Master Fund bought 1,538,462 common shares for $2,000,000.60 as part of a 32,000,000‑share underwritten public offering with a 4,800,000‑share option. The new preferred stock will automatically convert into common shares at a 50‑to‑1 ratio once shareholders approve an increase in authorized common shares and related charter steps are completed, subject to antitrust clearance where applicable.
Lexicon Pharmaceuticals has arranged a large equity financing through a public stock sale and related private placements involving its longtime investor Invus. The company agreed to sell 32,000,000 common shares at $1.30 per share, with underwriters holding a 30‑day option for 4,800,000 additional shares, for expected gross proceeds of about $41.6 million (or $47.84 million if the option is fully exercised), before fees.
Concurrently, Invus affiliates are purchasing 22,400,000 common shares at the same price for a total of $29.12 million, and an Invus affiliate will buy multiple tranches of Series B convertible preferred stock at $65 per share for expected gross proceeds of about $23.86 million (or $30.03 million if an additional option is fully used). Each preferred share converts into 50 common shares once shareholders approve a new charter increasing authorized common stock, the board adopts and files that charter, and any required Hart‑Scott‑Rodino clearances are obtained. After the offerings and the preferred conversion, Invus and related entities are expected to hold about 51% of Lexicon’s outstanding common stock, giving them majority ownership.
Lexicon Pharmaceuticals is offering 32,000,000 shares of common stock at $1.30 per share in a primary underwritten sale. Underwriters have a 30‑day option to buy up to 4,800,000 additional shares.
Affiliates of Invus, L.P., the largest stockholder, will buy 22,400,000 shares in a concurrent private placement at the same price, and are also purchasing two tranches of non‑voting convertible preferred stock at $65.00 per share that will convert into common stock on a 50‑to‑1 basis after shareholder approval to increase authorized shares and other conditions are met.
Lexicon expects net proceeds of approximately $79.9 million from the offering and the common stock private placement, or $91.9 million if all options are exercised, excluding additional net proceeds from the extra preferred shares. Funds will support continued research and development of its drug candidates, working capital and general corporate purposes. The company reported unaudited year‑end 2025 cash, investments and restricted cash of $125.2 million and a $10 million milestone from Novo Nordisk, with potential for up to an additional $20 million in 2026.